Shidong Ma Email & Phone Number

Pleasanton, Ca, Us

• Lead projects: accountable for project strategy; delivery, design, implementation, and analysis of in vitro and in vivo pharmacology data.• Focus on developing antibodies (bispecific, biparatopic, Ab-cytokine fusion) and ADCs as targeted therapy against cancer and auto-immune diseases.• Manage an in vivo pharmacology team to conduct in vivo studies: draft IACUC protocol, ensure compliance with the IACUC, model selection, model development, efficacy study, PK/PD study• Manage external CROs: choose CRO companies and coordinate with them to conduct in-vivo studies to generate IND-enabling data• In charge of company histopathology lab to do IHC, ISH, and IF staining to characterize tumor microenvironment and identify drug targets and biomarkers

Mountain View, California, Us

Lead a project team to generate in vitro and in vivo data for immune-oncology programs.• Develop CD3 T cell engager tumor-targeting bispecific IgM and IgM ADC (target validation, Ab campaign, and screen strategy, in vitro bio-functional assays, in vivo pharmacology (efficacy, PK/PD), and help cell line development department and QC group for assay development)• Set project strategies, ensure team productivity and effectiveness, and move projects forward on time and within budget• Manage a team to design, implement, and analyze in vitro and in vivo pharmacology data. Oversee the assay development.• Design and manage in vivo studies with internal in vivo team and external CROs • Work closely with collaborators and CROs during the discovery and development to generate IND-enabling data

In charge of company preclinical Pharmacology and Immuno-Oncology. Successfully moved projects forward by managing an in vivo team and outsourcing CROs.▪ Have successfully developed In Vivo modeling systems to evaluate the immune modulatory effects of biologics, for antitumor efficacy demonstration and candidate selection, as well as to explore MOA to test company developed biologics.▪ Independently responsible for authoring animal protocols and ensuring their authorization and compliance, including working closely together with the local IACUC committee and Animal Resources group.▪ CRO management including outsourced in vivo pharmacology and PD/PK studies.▪ In vitro and in vivo immune-oncology assays: in vitro cell killing assays, T cell functional assays, analyze tumor microenvironment from biologics treated animals.▪ Train, direct and oversee the experimentation of junior level research scientists.

Led tri-specific Ab project and successfully conducted innovative research to develop anti-tumor biologics.• Research to develop novel tri-specific anti-tumor antibodies.• Identify and characterize a variety of combinations of anti-tumor targets on a tri-specific antibody platform against various tumors. • Explore MOA of target combination on the tri-specific antibody platform.• Techniques such as in vitro binding assays, cell killing assays, T cell activation, proliferation assays, and in vivo efficacy studies with humanized mouse models are conducted.

Madison, Wi, Us

I was hired to plan and execute research projects, write manuscripts and grant proposals, and supervise graduate students.• Successfully developed humanized mouse (NOD/LtSz-scid /IL2R-/-) model with functional human immune cells. • Conduct research using the PD-1/CTLA-4 blockade to inhibit EBV-induced lymphomas in a humanized mouse model. • Utilize molecular biology techniques/methods, including gene cloning, PCR, bisulfite sequencing, in-situ hybridization, immunohistochemistry, and microscopy techniques. • T cell functional analysis, including proliferation and cytotoxicity assays and FACS technique. • Implement protein biochemistry practices, including SDS-Page gel electrophoresis and Western blotting. • Train undergraduate and graduate students in molecular, biochemical, immunohistochemistry, and other quantitative assays and technologies. • Use tissue/cell culture techniques, including transient transfections, lentiviral and retroviral infection/gene expression systems, and drug treatment using patient-derived cancer lines and humanized mouse models.• Published over ten papers in high-impact factor journals, such as the Journal of Clinical Investigation and PLoS Pathogens.

Minneapolis And St. Paul, Minnesota, Us

Chosen to provide research focused on characterizing gene expression in activated vs. resting bovine gamma/delta T cells and contrasted this EST expression data in two different systemic populations, peripheral blood, and spleen.• Analyzed the expression of cytokine, chemokine, and chemokine receptor genes in bovine peripheral gamma/delta T cells stimulated with mitogens over time.• Identified the bovine IL-22 gene and obtained the entire genomic sequence, cDNA sequence, and structure.• Characterized the regulation of IL-22 expression in bovine gamma/delta T cells stimulated by mitogens.• Superb laboratory technique skills, including site-directed mutagenesis, gene cloning, PCR, cell culture, reporter gene assays, and DNA-protein binding assays.• Successfully identified and characterized the IL-22 promoter and the transcription factor binding sites and described the IL-22 promoter function in primary bovine gamma/delta T cells using a GFP expression reporting system.

Doctor Of Philosophy, Molecular Veterinary Bioscience

Education record